Roche Introduces Online Software NimbleDesign Worldwide to Further Improve Target Enrichment Custom Design Process for Next-Generation Sequencing
Penzberg, Germany and Madison, WI, USA, June 21, 2013 / B3C newswire / - Roche today announced the global launch of the NimbleDesign tool, an online software that enables customers to easily design optimized SeqCap EZ Choice Libraries in as little as one hour. The software's industry-leading design algorithm offers an empirically optimized probe database allowing customers to obtain and review designs in an automated setting before making the purchase decision.
"NimbleDesign is based on years of target enrichment design experience from our bioinformatics experts," said Thomas Schinecker, President of Roche Sequencing Solutions. "Following the very positive feedback we received from pilot users in selected regions we are excited to offer this software tool globally now. It marks another step in our ongoing efforts to improve the customer convenience of our target enrichment portfolio."
The NimbleDesign tool enables customers to take full advantage of Roche's superior SeqCap EZ library technology, delivering more efficient discovery of Single Nucleotide Polymorphisms and better uniform coverage than many other commercially available technologies. In addition, the easy-to-use interface offers the opportunity to develop multiple designs simultaneously with very quick turnaround time. Adding to the already improved customer convenience with the launch of SeqCap EZ Reagents earlier this year, the NimbleDesign tool further streamlines the design workflow and ordering process.
For more information about Roche NimbleGen, please visit www.nimblegen.com
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
For life science research only. Not for use in diagnostic procedures.
NIMBLEDESIGN, NIMBLEGEN and SEQCAP are trademarks of Roche.
All other product names and trademarks are the property of their respective owners.
For further information please contact:
Dr. Claudia Schmitt
Phone: +49 8856 60 10210
Email: [email protected]